VeriSIM Life

08/09/2025

📰 Our latest op-ed in Marksmen Daily: https://hubs.li/Q03HlfyG0

At VeriSIM Life, we believe Hybrid AI is transforming drug development—speeding up candidate design, screening, and safety evaluation like never before. But with this acceleration comes a higher responsibility: ensuring transparency, traceability, and trust.

In our piece, we emphasize that innovation must go hand-in-hand with safety and public confidence. Hybrid AI isn’t just about moving faster, it’s about raising the safety bar for the entire industry.

Hybrid AI is accelerating drug development, but experts say transparency will be key to ensuring safety and building public trust.

02/09/2025

🚀 Excited to share a 𝗳𝗶𝗿𝘀𝘁-𝗼𝗳-𝗶𝘁𝘀-𝗸𝗶𝗻𝗱 𝗽𝘂𝗯𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻 from VeriSIM Life alongside Dr. Weida Tong!

We’ve pioneered a novel AI-driven framework to predict 𝗱𝗿𝘂𝗴-𝗶𝗻𝗱𝘂𝗰𝗲𝗱 𝗹𝗶𝘃𝗲𝗿 𝗶𝗻𝗷𝘂𝗿𝘆 (𝗗𝗜𝗟𝗜) — one of the leading causes of drug development failure and post-market withdrawals.

What makes this groundbreaking? We combined:

🔬 𝗥𝗮𝘁 𝗹𝗶𝘃𝗲𝗿 𝘁𝗿𝗮𝗻𝘀𝗰𝗿𝗶𝗽𝘁𝗼𝗺𝗶𝗰𝘀 – capturing rich biological signals
⚛️ 𝗤𝘂𝗮𝗻𝘁𝘂𝗺 𝗺𝗲𝗰𝗵𝗮𝗻𝗶𝗰𝘀-𝗱𝗲𝗿𝗶𝘃𝗲𝗱 𝗺𝗼𝗹𝗲𝗰𝘂𝗹𝗮𝗿 𝗳𝗲𝗮𝘁𝘂𝗿𝗲𝘀 – understanding drug behavior at a fundamental level
🧬 𝗣𝗵𝘆𝘀𝗶𝗼𝗹𝗼𝗴𝗶𝗰𝗮𝗹 𝘃𝗮𝗿𝗶𝗮𝗯𝗶𝗹𝗶𝘁𝘆 𝗱𝗮𝘁𝗮 – reflecting real-world patient diversity

By mechanistically integrating these data streams, our models achieve dramatically improved performance 𝗲𝘃𝗲𝗻 𝘄𝗶𝘁𝗵 𝗹𝗶𝗺𝗶𝘁𝗲𝗱 𝗱𝗮𝘁𝗮𝘀𝗲𝘁𝘀.

👉 This isn’t just about better early safety assessment. It’s a 𝘀𝗰𝗮𝗹𝗮𝗯𝗹𝗲, 𝗶𝗻𝘁𝗲𝗴𝗿𝗮𝘁𝗲𝗱 𝗮𝗽𝗽𝗿𝗼𝗮𝗰𝗵 that sets the stage for evaluating efficacy, safety, and target engagement far earlier in the preclinical pipeline.

This work highlights the 𝗽𝗼𝘄𝗲𝗿 𝗼𝗳 𝗰𝗼𝗺𝗯𝗶𝗻𝗶𝗻𝗴 𝗺𝗲𝗰𝗵𝗮𝗻𝗶𝘀𝘁𝗶𝗰 𝗯𝗶𝗼𝗹𝗼𝗴𝘆 𝘄𝗶𝘁𝗵 𝗮𝗱𝘃𝗮𝗻𝗰𝗲𝗱 𝗔𝗜 to reshape how the industry tackles some of its toughest translational challenges.

We are proud of the VeriSIM Life team for pushing the boundaries of what’s possible in drug development.

Check out the paper: https://hubs.li/Q03Gzsrg0

28/08/2025

🚀 Big News from VeriSIM Life!

We're thrilled to share that our Founder & CEO, Dr. Jo Varshney, has been awarded the 2025 International Women Entrepreneur Award in IT by Great Companies! 🏆🎉

This prestigious recognition honors visionary women who are redefining what's possible in the tech world, and Dr. Varshney is doing just that by leading innovation at the intersection of AI and biotechnology.

At the heart of this achievement is BIOiSIM™, our cutting-edge biosimulation platform that uses predictive modeling to simulate drug behavior in humans — reducing cost, time, and risk in drug development. 💊⚙️

👏 "This recognition is a testament not just to the technology we’ve built, but to the bold, interdisciplinary team that drives VeriSIM Life forward every day," said Dr. Varshney.

Since our founding in 2017, we've been on a mission to make drug development more humane, efficient, and effective — and this award highlights how far we've come.

Read the announcement: https://hubs.li/Q03G6wsl0

💡 What will it take to ensure more women not only enter but lead the next frontier of AI and biotech innovation? We'd love to hear your thoughts.👇

18/08/2025

🎉 Dr. Jo Varshney, a distinguished alumna who earned her PhD from the University of Minnesota, recently participated in two impactful panel discussions during the University's Bay Area Gatherings in Berkeley and Palo Alto! 🎓📍

As the Founder & CEO of VeriSIM Life and a leader in AI-driven healthcare innovation, Dr. Varshney brought powerful insights to the conversation, highlighting how cutting-edge technologies like artificial intelligence are shaping the future of life sciences and transforming drug development. 💡🧬

She joined fellow thought leaders and University of Minnesota President Dr. Rebecca Cunningham in celebrating the university’s legacy of research, education, and real-world impact.

This is just one look at the inspiring moments from these dynamic events! 📸

23/07/2025

Dr. Jo Varshney, Founder & CEO of VeriSIM Life, is guest lecturing at University of Pennsylvania's prestigious ITMAT program alongside Dr. Jeff Barrett, VP at Genmab, as part of the graduate course “Drug Development Decision Criteria.”

Dr. Varshney will lead the session “Opportunities for Artificial Intelligence in Drug Development Decision Making,” followed by a hands-on lab that explores how AI is transforming decisions from discovery through commercialization.

This ITMAT course at UPenn dives into key inflection points across the drug development lifecycle and examines how advanced technologies especially AI and simulation are reshaping the way we bring effective therapies to patients.

Dr. Varshney is proud to represent VeriSIM Life and share our work at the intersection of translational science and AI!

21/07/2025

🚀 VeriSIM Life is proud to be featured in BioTuesdays for our work transforming drug development with AI-powered predictive modeling!

Our CEO, Dr. Jo Varshney, shares how BIOiSIM® is helping researchers make smarter, faster decisions—reducing costs, cutting timelines, and improving clinical outcomes.

Read the full story: https://hubs.li/Q03y3Z1s0

14/07/2025

With FDA staffing and funding shortages causing regulatory bottlenecks, drug developers can’t afford to wait. This Marksmen Daily article sheds light on how AI is becoming a critical tool—not just for innovation, but for survival.

At VeriSIM Life, we see AI as a lifeline: enabling smarter preclinical decisions, reducing trial-and-error, and accelerating time-to-IND. 🧬⚡

🔗 Read the article: https://hubs.ly/Q03x5lfj0

💬 How is your team using AI to overcome regulatory slowdowns?

AI in healthcare regulation can help the FDA overcome staffing and funding gaps, ensuring faster, safer drug approvals and oversight.

07/07/2025

A big thank you to Informa TechTarget for recently sharing our byline, "Maximizing Biotech Investment Returns with AI"!

𝖪̲𝖾̲𝗒̲ ̲𝗍̲𝖺̲𝗄̲𝖾̲𝖺̲𝗐̲𝖺̲𝗒̲𝗌̲:

➞ Faster Drug Development: AI accelerates the discovery and delivery of therapies.
➞ Cost Efficiency: AI optimizes drug development, reducing costs.
➞ Better Predictions: AI improves clinical trial success rates.

At VeriSIM Life, we’re proud to lead the way with our BIOiSIM platform, revolutionizing drug development through AI.

Read now: https://hubs.li/Q03w52GD0

27/06/2025

We are proud to share that Dr. Varshney, a distinguished alumni who received her PhD from University of Minnesota, has been invited to participate in two impactful panel discussions when the university visits the Bay area! 🎓

As a leader in the field, Dr. Varshney’s contributions to healthcare innovation and AI-driven technologies have made a significant mark on the industry. It’s an honor for her to join thought leaders in these discussions, where they will explore the future of life sciences and the role of cutting-edge technologies in shaping tomorrow's healthcare landscape. 💡

Learn more: https://hubs.li/Q03v39gm0

25/06/2025

🚨 Big News! 🚨

We’re thrilled to share that VeriSIM Life has been named Machine Learning Platform of the Year by the 2025 AI Breakthrough Awards!

This recognition is a testament to our team's relentless innovation, and the power of our BioSIM™ platform, which is redefining how drugs are developed—faster, safer, and without relying on animal testing. 🧠💊🧬

At VeriSIM, we're not just applying AI—we’re pushing the boundaries of what’s possible in biotech and pharmaceutical R&D with predictive simulations that de-risk decisions and accelerate timelines.

Huge congratulations to our brilliant team and thank you to AI Breakthrough for this honor! 🙌 https://hubs.li/Q03tCpj80

20/06/2025

🚫🐁 The end of animal testing? The FDA thinks so — and so do we. ✅💡

With the FDA’s new roadmap endorsing AI and human-relevant models for drug development, we’re entering a bold new era of science — one VeriSIM Life has been building for years.

At VSL, we create digital humans. Real biology, real results. Our AI-driven platform has already guided therapies into clinical trials — faster, safer, smarter. ⚡

🧪 81% clinical prediction accuracy
🧠 Models across 60+ diseases
💥 4 client programs in trials now

👇 Check out the blog, then let's discuss: Will AI fully replace animals in preclinical testing? What ethical or regulatory shifts do you want to see next? https://hubs.li/Q03t1G_50

16/06/2025

🚀 VeriSIM Life was featured in Newsweek for our role in addressing challenges in clinical trials and drug discovery amid funding cuts.

🔬 As highlighted in the article, our digital twin technology helps simulate drug effects, accelerating development while reducing costs. Even as NIH funding faces cuts, innovation in healthcare must continue, and we’re committed to driving that progress.

💡 "Science cannot wait." – Dr. Jo Varshney, CEO

👉 Read more here: https://hubs.li/Q03sg1xV0

What happens when scientific research's reckoning coincides with AI's golden age?